Academic Journal
Q1BioDrugs
About BioDrugs
BioDrugs is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q1, with an SJR of 2.628 and H-index of 90.
Coverage: 1996-2026. Research categories: Biotechnology (Q1); Medicine (miscellaneous) (Q1); Pharmacology (Q1); Pharmacology (medical) (Q1).
Verified field sources
- Journal Impact Factor: 8.5 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Biosimilars and Bioanalytical Methods; Monoclonal and Polyclonal Antibodies Research; Rheumatoid Arthritis Research and Therapies; Immunotherapy and Immune Responses; CAR-T cell therapy research; Asthma and respiratory diseases.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
5,190.00 USD; 4,190.00 EUR; 3,590.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate
Björn Capsius, Marija Pesic, Ravil Niyazov, Susanne Pippig et al.
2026-09-19 · DOI: 10.1007/s40259-026-00803-yPlant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects
Qiang Chen
2026-09-17 · DOI: 10.1007/s40259-026-00811-yBiologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases
Liyan Qiu, Jonas Torbjörn Ungerbäck, Eric Paul Bennett, Rasmus O. Bak et al.
2026-09-14 · DOI: 10.1007/s40259-026-00804-xBiosimilars: A Virtuous Cycle of Sustainability and Innovation
Fernando de Mora, Vicente Merino-Bohórquez, Rosario García-Vicuña, Isabel Río-Álvarez et al.
2026-09-14 · DOI: 10.1007/s40259-026-00806-9Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk
Ted R. Mikuls, Tuhina Neogi, Angelo Gaffo
2026-09-14 · DOI: 10.1007/s40259-026-00808-7The Effect of Anti-drug Antibodies on the Bioavailability of Alglucosidase Alfa in Classic Infantile Pompe Disease
Martha Caterina Faraguna, Daniël A. M. Lambregts, Ina Barzel, Edwin H. Jacobs et al.
2026-09-11 · DOI: 10.1007/s40259-026-00802-zTargeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability
Lourdes Sainero-Alcolado, Dilraj Lama, Mohammad Alzrigat, Marie Arsenian-Henriksson et al.
2026-09 · DOI: 10.1007/s40259-026-00798-6Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial
Oh Chan Kwon, Soo Min Ahn, Seokchan Hong, Yeon Hong Seo et al.
2026-09 · DOI: 10.1007/s40259-026-00805-wTargeting CD38 Across Autoimmune and Plasma Cell–Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape
Dario Roccatello, Savino Sciascia, Daniela Rossi, Roberta Fenoglio et al.
2026-09 · DOI: 10.1007/s40259-026-00799-5Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study
Xin Ma, Yue Jiang, Dongmei Liu, Quanruo Xu et al.
2026-09 · DOI: 10.1007/s40259-026-00801-0Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer
Taekyung Kim, Heungjo Kim, Hongjae Lee, Keumyoung Ahn et al.
2026-09 · DOI: 10.1007/s40259-026-00800-1Expanding Patient Access to Advanced Therapies
Elena Guillen, Ana Hidalgo-Simon
2026-09 · DOI: 10.1007/s40259-026-00797-7Home Infusion With Recombinant Human α-Glucosidase in Children With Pompe Disease: The Dutch Experience Over 20 Years Across the Spectrum From Classic Infantile to Late-Onset Phenotypes
Imke A. M. Ditters, Hidde H. Huidekoper, Jacqueline F. Hardon, Michelle E. Kruijshaar et al.
2026-09 · DOI: 10.1007/s40259-026-00773-1Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same
Joseph P. Park, Hyunhee Oh, Gillian R. Woollett
2026-09 · DOI: 10.1007/s40259-026-00796-8Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis
Carlos Roberto Montes-de-Oca-Saucedo, Laura Ghanem, Najwaa Kirmani, Bruno Briceño-Villardaga et al.
2026-09 · DOI: 10.1007/s40259-026-00795-9Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials
Zhihua Ran, Yan Chen, Yinglei Miao, Yufang Wang et al.
2026-07 · DOI: 10.1007/s40259-026-00793-xGene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities
Rebecca J. Wilson, Charmaine A. Ramlogan-Steel, William J. Deasy, Sarah J. Greenstein et al.
2026-09 · DOI: 10.1007/s40259-026-00794-wAn Overview and Trend Analysis of Biosimilar Approvals in China
Mei Yang, Ning Zhang, Haixue Wang
2026-07 · DOI: 10.1007/s40259-026-00788-8Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab
Anika M. Valk, Jolinde van Strien, Ninotska Derksen, Dorien Kos et al.
2026-07 · DOI: 10.1007/s40259-026-00792-yReview of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union
Rakesh Aithal, Olivia M. Majedi, Diane McCarthy, Fouad Atouf et al.
2026-07 · DOI: 10.1007/s40259-026-00786-wReviews
Community Reviews
Version History
October 4, 2026 at 8:45 pm
September 18, 2026